Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by francoisl13on Aug 04, 2023 1:48pm
128 Views
Post# 35573775

RE:RE:RE:RE:RE:We will survive ?

RE:RE:RE:RE:RE:We will survive ?Thanks RoyMax123 for the clarifications regarding the initial investment by Animalcare, I got my secnd sets of #'s froma KNE press release, anyway, it looks better when using 5M...:)
There is some nice catalysts coming our way that could help them getting some cash flow, they are;
1. Coactiv+ sales picking-up in the USA (they are having some issues at their manufacturing sub-contractor site that should get resolved late Q3);
2. Improvement in pet products sales -- Animalcare mentioned in their last report that Plaqtiv+ is off to a good start. They also have a specific website for this product -- see link: Plaqtiv+
3. Skout's -- no news yet but they must be close to be ready to launch their product line;
4. As you noted, dermatology could become a real factor here since this type of product can be sold OTC and have quick market penetration should you pick the right path to market.
Anyway, I like KNE management and how this story is unfolding despite the fact that it happens a little too slowly.
GLTA
<< Previous
Bullboard Posts
Next >>